Circulating suPAR in two cohorts of primary FSGS

• Verfasst von: Wei, Changli [VerfasserIn]
• Verfasst von: Heil, Karsten M. [VerfasserIn]
• Verfasst von: Trautmann, Agnes [VerfasserIn]
• Verfasst von: Schaefer, Franz [VerfasserIn]
• Titel: Circulating suPAR in two cohorts of primary FSGS
• Verf.angabe: Changli Wei, Howard Trachtman, Jing Li, Chuanhui Dong, Aaron L. Friedman, Jennifer J. Gassman, June L. McMahan, Milena Radeva, Karsten M. Heil, Agnes Trautmann, Ali Anarat, Sevinc Emre, Gian M. Ghiggeri, Fatih Ozaltin, Dieter Haffner, Debbie S. Gipson, Frederick Kaskel, Dagmar-Christiane Fischer, Franz Schaefer, Jochen Reiser, for the PodoNet and FSGS CT Study Consortia
• Jahr: 2012
• Umfang: 9 S.
• Fussnoten: Gesehen am 30.04.2019
• Titel Quelle: Enthalten in: American Society of NephrologyJournal of the American Society of Nephrology
• Ort Quelle: Washington, DC : American Society of Nephrology, 1990
• Jahr Quelle: 2012
• Band/Heft Quelle: 23(2012), 12, Seite 2051-2059
• ISSN Quelle: 1533-3450
• DOI: doi:10.1681/ASN.2012030302
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1663760705

Abstract

Overexpression of soluble urokinase receptor (suPAR) causes pathology in animal models similar to primary FSGS, and one recent study demonstrated elevated levels of serum suPAR in patients with the disease. Here, we analyzed circulating suPAR levels in two cohorts of children and adults with biopsy-proven primary FSGS: 70 patients from the North America-based FSGS clinical trial (CT) and 94 patients from PodoNet, the Europe-based consortium studying steroid-resistant nephrotic syndrome. Circulating suPAR levels were elevated in 84.3% and 55.3% of patients with FSGS patients in the CT and PodoNet cohorts, respectively, compared with 6% of controls (P<0.0001); inflammation did not account for this difference. Multiple regression analysis suggested that lower suPAR levels associated with higher estimated GFR, male sex, and treatment with mycophenolate mofetil. In the CT cohort, there was a positive association between the relative reduction of suPAR after 26 weeks of treatment and reduction of proteinuria, with higher odds for complete remission (P=0.04). In the PodoNet cohort, patients with an NPHS2 mutation had higher suPAR levels than those without a mutation. In conclusion, suPAR levels are elevated in geographically and ethnically diverse patients with FSGS and do not reflect a nonspecific proinflammatory milieu. The associations between a change in circulating suPAR with different therapeutic regimens and with remission support the role of suPAR in the pathogenesis of FSGS.